PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1476-5381|172|17|4277-4290

ISSN： 0007-1188

Source： BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol.172, Iss.17, 2015-09, pp. : 4277-4290

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Looking into cognitive impairment in primary‐progressive multiple sclerosis

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 1, 2018-01 ,pp. : 192-195

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ten‐year prognosis in multiple sclerosis: a better outcome in relapsing−remitting patients but not in primary progressive patients

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 22, Iss. 3, 2015-03 ,pp. : 507-e35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progressive resistance exercise for people with multiple sclerosis

By Taylor N.   Dodd K.   Prasad D.   Denisenko S.  

Disability and Rehabilitation, Vol. 28, Iss. 18, 2006-09 ,pp. : 1119-1126

Informa Healthcare

Access to resources Recommend Favorite

Mitoxantrone in secondary progressive multiple sclerosis: a review of toxicity in 41 patients

By Peak Scott   Tsao-Wei Denice D   Chamberlain Marc C  

Therapy, Vol. 4, Iss. 1, 2007-01 ,pp. : 55-58

Future Medicine

Access to resources Recommend Favorite

A qualitative analysis of a progressive resistance exercise programme for people with multiple sclerosis

By Dodd K.   Taylor N.   Denisenko S.   Prasad D.  

Disability and Rehabilitation, Vol. 28, Iss. 18, 2006-09 ,pp. : 1127-1134

Informa Healthcare

Access to resources Recommend Favorite